Why is a continuous daily dose of prednisolone administered with cabazitaxel chemotherapy?

Why Daily Prednisolone is Given with Cabazitaxel

Daily prednisolone 10 mg is mandated throughout cabazitaxel therapy because it is an integral component of the FDA-approved regimen that demonstrated survival benefit in the pivotal TROPIC trial, though the precise mechanism by which prednisolone enhances cabazitaxel efficacy remains incompletely understood. 1

Regulatory Requirement and Evidence Base

• The FDA approval of cabazitaxel explicitly requires administration "in combination with oral prednisone 10 mg administered daily throughout Cabazitaxel Injection treatment." 1
• The landmark TROPIC trial that established cabazitaxel's 2.4-month survival advantage over mitoxantrone (HR 0.70, p<0.0001) administered both drugs with daily prednisone 10 mg, making this combination the evidence-based standard. 2, 3
• Similarly, the CARD trial demonstrating superior overall survival with cabazitaxel versus androgen-signaling inhibitors (13.6 vs 11.0 months; HR 0.64) used concurrent daily corticosteroids. 2, 4

Distinction from Premedication Corticosteroids

It is critical to understand that daily prednisolone serves a different purpose than the premedication corticosteroid given before each infusion:

• Premedication corticosteroid (dexamethasone 8 mg IV given 30 minutes before infusion) prevents acute hypersensitivity reactions to cabazitaxel. 4, 1
• Daily oral prednisolone (10 mg continuously) is part of the therapeutic regimen itself, not merely supportive care. 1

Potential Mechanisms (Incompletely Defined)

While the exact role remains unclear, several hypotheses exist:

• Synergistic antitumor activity: Corticosteroids may have direct anti-lymphoma effects in prostate cancer or modulate the tumor microenvironment. 5, 6
• Symptom palliation: Low-dose corticosteroids provide analgesic and anti-inflammatory benefits in metastatic disease. 5
• Historical precedent: Docetaxel regimens in prostate cancer also routinely include daily prednisone, establishing this as standard practice for taxane therapy in mCRPC. 2

Controversial Evidence on Necessity

One retrospective single-institution study challenged the necessity of daily prednisone:

• A 2017 Italian analysis of 91 deceased mCRPC patients found no significant difference in overall survival between those receiving cabazitaxel with daily prednisone (9 months) versus without (14 months), though this difference was not statistically significant on multivariable analysis. 7
• The authors concluded that omitting daily corticosteroids had "no negative impact on either survival or safety profile" and launched the prospective CABACARE trial to definitively test this question. 7

However, this single retrospective study cannot override the FDA-mandated regimen:

• The study was underpowered, retrospective, and conducted at a single center. 7
• All pivotal trials (TROPIC, CARD, PROSELICA) that established cabazitaxel's efficacy used daily prednisone, making deviation from this regimen off-label. 2, 4, 3
• Until prospective randomized data demonstrate non-inferiority of cabazitaxel without corticosteroids, the standard remains daily prednisolone 10 mg. 4, 1

Clinical Implementation

The following approach should be followed:

• Prescribe oral prednisolone (or prednisone) 10 mg daily starting with the first cabazitaxel cycle and continuing throughout treatment. 4, 1
• This is in addition to premedication with IV dexamethasone 8 mg (or equivalent) given 30 minutes before each cabazitaxel infusion. 4, 1
• Do not substitute or omit the daily corticosteroid, as this represents deviation from the evidence-based, FDA-approved regimen. 1

Common Pitfalls to Avoid

• Confusing premedication with daily therapy: Some clinicians mistakenly believe the preinfusion dexamethasone replaces the need for daily prednisolone—both are required. 4, 1
• Omitting daily corticosteroids based on single retrospective data: The CABACARE trial results are pending; until then, daily prednisolone remains mandatory per FDA labeling. 1, 7
• Failing to counsel patients on corticosteroid side effects: Long-term low-dose corticosteroids carry risks of hyperglycemia, osteoporosis, and immunosuppression that require monitoring. 1